Epidermal growth factor receptor‑tyrosine kinase inhibitors for non‑small‑cell lung cancer patients aged 80 years or older: A retrospective analysis

Nakao,Makoto; Muramatsu,Hideki; Sone,Kazuki; Aoki,Sachiko; Akiko,Harata; Kagawa,Yusuke; Sato,Hidefumi; Kunieda,Takefumi

doi:10.3892/mco.2014.453

Epidermal growth factor receptor‑tyrosine kinase inhibitors for non‑small‑cell lung cancer patients aged 80 years or older: A retrospective analysis

Authors:
- Makoto Nakao
- Hideki Muramatsu
- Kazuki Sone
- Sachiko Aoki
- Harata Akiko
- Yusuke Kagawa
- Hidefumi Sato
- Takefumi Kunieda
View Affiliations

Affiliations: Department of Respiratory Medicine, Kainan Hospital, Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498‑8502, Japan, Department of Respiratory Medicine, Nagoya City East Medical Center, Nagoya, Aichi 464-8547, Japan
Published online on: November 5, 2014 https://doi.org/10.3892/mco.2014.453
Pages: 403-407

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The efficacy of epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) in elderly patients with non‑small‑cell lung cancer (NSCLC) remains uncertain. This retrospective study aimed to evaluate the efficacy and feasibility of EGFR‑TKIs for NSCLC patients aged ≥80 years. We analyzed data from 21 NSCLC patients aged ≥80 years who were administered gefitinib and/or erlotinib between January, 2009 and December, 2014. The clinical characteristics, smoking status, type of EFGR mutation and the efficacy and toxicity of EGFR‑TKIs were evaluated in these patients. In total, 14 (66.7%), 5 (23.8%) and 2 patients (9.5%) displayed partial response, stable disease and progressive disease, respectively. The median progression‑free survival was 182 days, whereas the median overall survival was 371 days. adverse events ≥grade 2 were as follows: skin toxicities, 12 patients; liver function test abnormalities, 7 patients; anorexia, 3 patients; and diarrhea, 2 patients. Dose reduction of EGFR‑TKIs due to adverse events was required in 15 patients (71.4%). Although gefitinib and erlotinib therapy may be beneficial in patients aged ≥80 years, EGFR‑TKI dose modification may be necessary according to the overall medical condition of elderly patients. Further studies are required to evaluate our findings.

View Figures

View References

1	Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2:533–543. 2001. View Article : Google Scholar : PubMed/NCBI
2	Inoue A, Kobayashi K, Usui K, et al: First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 27:1394–1400. 2009. View Article : Google Scholar : PubMed/NCBI
3	Maemondo M, Minegishi Y, Inoue A, et al: First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 7:1417–1422. 2012. View Article : Google Scholar : PubMed/NCBI
4	Hotta K, Ueoka H, Kiura K, et al: Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Acta Oncol. 44:717–722. 2005. View Article : Google Scholar : PubMed/NCBI
5	Bunn PA Jr and Lilenbaum R: Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 95:341–343. 2003. View Article : Google Scholar : PubMed/NCBI
6	Owonikoko TK, Ragin CC, Belani CP, et al: Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 25:5570–5577. 2007. View Article : Google Scholar : PubMed/NCBI
7	Kobayashi M, Matsui K, Katakami N, et al West Japan Oncology Group: Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan thoracic oncology group study 0402. Jpn J Clin Oncol. 41:948–952. 2011. View Article : Google Scholar : PubMed/NCBI
8	Uruga H, Kishi K, Fujii T, et al: Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis. Intern Med. 49:103–107. 2010. View Article : Google Scholar : PubMed/NCBI
9	Asami K, Koizumi T, Hirai K, et al: Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. Clin Lung Cancer. 12:387–392. 2011. View Article : Google Scholar : PubMed/NCBI
10	Rossi D, Dennetta D, Ugolini M, et al: Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial. Target Oncol. 5:231–235. 2010. View Article : Google Scholar : PubMed/NCBI
11	Jackman DM, Yeap BY, Lindeman NI, et al: Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 25:760–766. 2007. View Article : Google Scholar : PubMed/NCBI
12	Togashi Y, Masago K, Fujita S, et al: Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer. 74:98–102. 2011. View Article : Google Scholar : PubMed/NCBI
13	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
14	Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246. 2003. View Article : Google Scholar : PubMed/NCBI
15	Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 65:7276–7282. 2005. View Article : Google Scholar : PubMed/NCBI
16	Yoshida K, Yatabe Y, Park JY, et al: Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol. 2:22–28. 2007. View Article : Google Scholar : PubMed/NCBI
17	Goldstraw P, Crowley J, Chansky K, et al International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
18	Eisenhauer EA1, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
19	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
20	Ebi N, Semba H, Tokunaga SJ, et al: A phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol. 3:1166–1171. 2008. View Article : Google Scholar : PubMed/NCBI
21	Tateishi K, Ichiyama T, Hirai K, et al: Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study. Med Oncol. 30:4502013. View Article : Google Scholar : PubMed/NCBI
22	Chrischilles EA, Pendergast JF, Kahn KL, et al: Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 28:620–627. 2010. View Article : Google Scholar : PubMed/NCBI
23	Wheatley-Price P, Ding K, Seymour L, Clark GM and Shepherd FA: Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21. J Clin Oncol. 26:2350–2357. 2008. View Article : Google Scholar : PubMed/NCBI
24	Kudoh S, Kato H, Nishiwaki Y, et al: Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI
25	Satoh H, Inoue A, Kobayashi K, et al: Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol. 6:1413–1417. 2011. View Article : Google Scholar : PubMed/NCBI
26	Goto K, Nishio M, Yamamoto N, et al: A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer. 82:109–114. 2013. View Article : Google Scholar : PubMed/NCBI